{"id":"W4382794886","doi":"10.1016/j.annonc.2023.06.009","title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Janssen Research and Development; National Cancer Institute; Genentech; Astellas Pharma; Ipsen; Clovis Oncology; Taiho Pharmaceutical; Gilead Sciences; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Takeda Oncology; Amgen; Pfizer; Daiichi Sankyo Europe; Sanofi; Abbott Laboratories","keywords":"Medicine; Abiraterone acetate; Interim analysis; Prednisone; Prostate cancer; Hazard ratio; Internal medicine; Progression-free survival; Urology; Oncology; Chemotherapy; Confidence interval; Gastroenterology; Androgen deprivation therapy; Randomized controlled trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008077268,0.0001523245,0.001038409,0.0004850648,0.00006198056,0.0000116943,0.00006417847,0.00005233069,0.00006232935],"category_scores_gemma":[0.00009026934,0.00008457278,0.0001134743,0.001051666,0.0003850435,0.0001139401,0.00003701536,0.000124611,4.22908e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009839766,"about_ca_system_score_gemma":0.0006179163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000427061,"about_ca_topic_score_gemma":0.002529739,"domain_scores_codex":[0.9982051,0.0003812012,0.0006344459,0.0002758592,0.0002699758,0.000233465],"domain_scores_gemma":[0.9985867,0.0002241402,0.0004309738,0.0002166285,0.0004802474,0.00006134578],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.976165,0.001657491,0.006343034,0.0001802433,0.005400755,0.00005906031,0.003481311,0.0006426948,0.001813862,0.00002754096,0.0001616837,0.004067331],"study_design_scores_gemma":[0.926277,0.01487775,0.04738759,0.0001337392,0.002047913,0.000003419896,0.0003331609,0.002135912,0.006540847,0.00008636175,0.00005043402,0.0001258131],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948626,0.0003932297,0.0000101998,0.001222714,0.00006066465,0.003170148,0.0001867222,0.000017863,0.00007592473],"genre_scores_gemma":[0.997402,0.0005257247,0.0002376875,0.00008132388,0.000009607576,0.0007005283,0.0003477804,0.00001345347,0.0006819143],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04988793,"threshold_uncertainty_score":0.3448778,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0673827402915172,"score_gpt":0.3994581347533062,"score_spread":0.332075394461789,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}